Back Bay Advised Caladrius Biosciences on Merger with Cend Therapeutics

Back Bay Life Science Advisors is proud to have served as strategic and financial advisors to Caladrius Biosciences, now called Lisata Therapeutics, on its merger with Cend Therapeutics, announced earlier this week.

The transaction combines management skills, inflection-point science and trials funding to create a new company with significant potential for both patients and investors.

According to the company press release, the merged company will focus primarily on advancing its CendR Platform™ technology product candidates in a range of oncology indications, in addition to Caladrius’ existing development programs.

Starting September 15, 2022, Lisata will trade on The Nasdaq Capital market, under the ticker symbol, “LSTA”.

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease. Cend is a privately held, clinical-stage drug discovery and development company focused on a novel approach to enable more effective treatments for solid tumor cancers.

Read about their stock agreement: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics.

 Connect with our investment banking team for questions on transaction preparedness.